Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Overview
Date Founded

2003

Headquarters

300 THIRD STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142

Type of Company

Public

Employees (Worldwide)

1,323

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Alnylam Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President & Chief Operating Officer

Chief Financial & Accounting Officer

Chief Commercial Officer

Chief Ethics & Compliance Officer

Chief Information Officer & Senior Vice President

Chief Medical Officer

Executive Vice President, Chief Legal Officer & Secretary

Chief Human Resources Officer & Senior Vice President

Vice President, Associate General Counsel

Board of Directors

Executive Officer, Director at Adolor Corp.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Co-Founder at Lyndra Therapeutics, Inc.

President at International Council of Ophthalmology Foundation

Former Venture Partner at Third Rock Ventures LLC

Former Chief Financial Officer & Senior Vice President at Takeda Oncology Co.

Former Foreign Secretary at Institute of Medicine

Vice President & Member at European Federation Of Pharmaceutical Industries And Associations

Former Executive Vice President & Chief Operating Officer at Health Care Service Corp.

Physician in Chief Emeritus of Medicine at The Massachusetts General Hospital

Paths to Alnylam Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Alnylam Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

FCM seeks investments across asset classes and around the world through a process of bottom-up fundamental research and analysis emphasizing capital preservation. Their investment strategies include Credit Investments, Long/Short Equity, Merger Arbitrage, Risk Arbitrage, Real Estate Investments and Direct Investments. Investment ideas compete for capital based on in-depth, critical assessment of specific risks and rewards. Risk is monitored and managed through rigorous and thorough analysis of each investment and, at the portfolio level, through risk management analytics and overlay and tail-risk hedging.

Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges. The firm’s research process will be focused on a scientific approach to assessing and accurately defining the fundamental value of outcomes surrounding transformational events in the lifecycle of healthcare companies.

Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Recent Transactions
Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Goodwin Procter LLP

Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Key Stats and Financials As of 2019
Market Capitalization
$19.2B
Total Enterprise Value
$11.4B
Earnings Per Share
$-8.11
Revenue
$220M
Net Profit
$-886M
Total Debt
$304M
Total Equity
$1.44B
Debt TEV
0.03x
Five Year Compounded Annual Growth Rate Of Revenue
34.16%
Three Year Compounded Annual Growth Rate Of Revenue
67.03%
TEVNet Income
-12.81x
Enterprise Value / Sales
51.66x
EBITDAMargin
-419.68%
EBITDA
$-922M
Non-Profit Donations & Grants
$2,500 - $4,999
2018
$5,000 - $10K
2017
Investors
Details Hidden

Investor at Alnylam Pharmaceuticals, Inc.

Details Hidden

Cardinal Partners invests in life sciences, medical devices and healthcare information technology. The firm provides financing for early-stage companies with an investment size of $6 million to $12 million. It leads initial round of investment.

Details Hidden

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, MA

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Cancer Research UK Hospitals & Patient Services | London, United Kingdom

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Arbutus Biopharma Corp. Pharmaceuticals - Burnaby, Canada

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
2009
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alnylam Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alnylam Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alnylam Pharmaceuticals, Inc..